Abstract: This disclosure relates to diagnostic assays useful to detect a carcinoma from a sample and antibodies or binding fragments thereof useful in the diagnostic tests. In certain embodiments, this disclosure relates to antibodies or fragments that bind HCA, epiglycanin, and/or fragments thereof. In certain embodiments, this disclosure relates to anti-idiotypic antibodies or fragments that bind the variable regions of antibodies that bind HCA and/or epiglycanin.

Abstract: The invention provides a compound of formula I, formula II, or formula III: or a salt thereof, wherein R1-R10 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as HIV-1 CA-targeting molecules and as antiviral agents.

Abstract: This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.

Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.

Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

Abstract: This disclosure relates to styrylbenzothiazole derivatives for use as in vivo imaging agents for the diagnosis of Parkinson's disease (PD) or other degenerative disorders or conditions of the central nervous system. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms.

Abstract: This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.

Abstract: Systems relate to a reusable console system that can be used with a plurality of different types of disposable cassettes. The cassettes may be structured for different therapies, different fluid volumes, among others, or a combination thereof. The disposable cassette may include a plurality of fluid circuits. Each circuit may include a pump chamber disposed along the path. The disposable cassette and the panel of a console may be configured to mate so that each of the one or more actuators of the console align with a pump chamber of the disposable cassette. The console may be configured to control a flow of the fluid in the path in the cassette when the disposable cassette is mated on the panel. Because the console can be mated with different cassettes, the system can efficiently and accurately deliver different medical fluid therapies and/or different patient populations (e.g., pediatric and adult).

Abstract: The systems and methods can accurately and efficiently determine boundary conditions for an arterial segment and thereby efficiently determine hemodynamic information for that segment. The method may include receiving medical image data of a patient. The method may further include generating a geometrical representation of the one or more arterial segments from the medical image data. The method may further include determining boundaries and geometry data for each arterial segment. The method may further include determining boundary conditions for the inflow boundary and each outflow boundary. The boundary conditions for each outflow boundary may be determined using an outflow distribution parameter. The outflow distribution parameter may be determined using the geometry data for one or more of the one or more outflow boundaries, stored hemodynamic data, or a combination thereof. The method may further include determining flow field for each arterial segment and determining hemodynamic information.

Abstract: Compositions and methods of modulating an innate immune response with circular RNAs are disclosed. In particular, the disclosure relates to methods for modifying an RNA by circularization and the use of circular RNAs generated with exogenous introns to stimulate an innate immune response or circular RNAs generated with endogenous introns to prevent immune recognition of foreign RNA.

Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.

Abstract: The disclosure concerns a method of treating complications of acute or chronic hyperglycemia and/or diet-induced obesity comprising: (i) determining whether a patient suffers from complications related to acute or chronic hyperglycemia and/or diet induced obesity, and if so, (ii) administering to the patient in need thereof a selective inhibitor of soluble TNF-? but not transmembrane TNF-?. For purposes herein, complications of acute or chronic hyperglycemia and/or diet-induced obesity include: diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, and chronic intestinal inflammation.

Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.

Abstract: Mesofluidic devices for culturing cell aggregates and methods of using the same are disclosed. An exemplary mesofluidic device comprises at least one fluid inlet, at least one fluid outlet, a plurality of fluid channels, and a plurality of culture chambers. Each culture chamber can comprise at least one chamber inlet and at least one chamber outlet. The at least one chamber inlet can be in fluid communication with the at least one fluid inlet via at least one of the plurality of fluid channels. The at least one chamber outlet can be in fluid communication with the at least one fluid outlet via at least one of the plurality of fluid channels. The mesofluidic device can be configured to contain a cell aggregate in each of the plurality of culture chambers.

Abstract: Compounds, compositions, and methods of treatment and prevention of Hepacivirus, Pestivirus, Flavivirus or Alphavirus infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of Hepacivirus, Pestivirus, Flavivirus or Alphavirus in an infected patient.

Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.

Abstract: The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. The present disclosure also relates to methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

Abstract: A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.